A two-way investment channel between the United States and Mexico — connecting off-market, private U.S. biotech and pharma dealflow with a closed network of LATAM capital, industrial operators, and strategic partners.
The first structured biotech channel between the U.S. and Mexico.
The conversations that define global biotech happen in rooms in New York, Boston, and San Francisco. Argentina is there. Chile is there. India, Canada, Europe — all there.
Mexico is claiming a seat at that table.
Scirena operates the first structured channel of its kind — connecting Mexican and U.S. capital, scientists, and industrial operators on both sides of the border into private, off-market deal flow that moves in both directions.
United States
Biotech · Pharma · U.S. Capital
Early-stage biotech and pharma dealflow
U.S.-based investors and emerging funds
Technology and platform innovation
Cross-border structuring expertise
Scirena
Mexico
Scientific Talent · Research Facilities · Industrial Capital
LATAM family offices and private capital
Major industry and manufacturing operators
Scientists and university research facilities
Latin American strategic and commercial networks
With selective activity across broader Latin America and global markets where strategic alignment exists.
Investment Focus
Where we deploy attention and capital
Biotech & Life Sciences
Platform technologies, therapeutics, and tools with defensible scientific foundations and clear commercial paths.
Industrial Biotech / Biomaterials
Biology applied to materials, manufacturing, and industrial processes — sectors ready for biological disruption.
Energy & Climate-Linked Systems
Opportunities at the intersection of biology, energy transition, and sustainable infrastructure — across U.S. and Latin American markets.
Biology × Infrastructure
Convergence plays where biological innovation meets large-scale industrial or infrastructure deployment in U.S. and Latin American markets.
Supported by a network of legal, M&A, and C-suite advisors — biotech executives, pharma operators, and cross-border structuring specialists across the United States and Mexico — engaged deal-by-deal.
Participation is selective. We are not looking for passive capital — we are looking for operators, connectors, and industry leaders who understand that building this channel requires strategic presence, not just financial exposure.
Consulting Services
Strategic Advisory & Commercial Execution
Supporting biotech and industrial companies in positioning, partnerships, and market access across the U.S.–Latin America corridor.
Biotech companies, CROs, and technical platforms with strong scientific foundations and clear commercial ambition — particularly those with cross-border relevance between U.S. and Latin American markets.
We work with a limited number of companies at any time. Engagements are selective.
Submit Your Deck for Review
If you're building something technically strong with real commercial potential, submit your materials for consideration.
The next generation of biotech is cross-border. You're being invited to help build it. A few quick details, and our team will follow up directly with your formal Letter of Intent for Fund I.
Private & Confidential — By Invitation Only
Fund at a Glance
Scirena BioVentures Fund I is a seed-stage vehicle investing across pharma, biotech, and climate tech at the U.S.–Mexico corridor — where scientific innovation in Mexico meets U.S. capital, infrastructure, and market access. Structured as a traditional 2/20 fund (2% management fee, 20% carried interest), Fund I's first close is targeted for February 2027.
